- Researchers to highlight positive results from the Phase 3
PROGRESS trial investigating atogepant (QULIPTA™) for the
preventive treatment of chronic migraine
- Breadth of research underscores AbbVie's leadership and
commitment to people living with migraine and their individual
needs
NORTH
CHICAGO, Ill., June 7, 2022
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present
data from its migraine portfolio at the 2022 American Headache
Society (AHS) Annual Scientific Meeting to be held in Denver, June
9-12. A total of 29 abstracts, including two oral
presentations and one late-breaker presentation, will cover a wide
range of studies across AbbVie's migraine portfolio, and highlight
the company's newest migraine treatment, atogepant (QULIPTA).
"As the only pharmaceutical company that offers three products
that span the spectrum of migraine treatment, which include
preventive therapies for chronic and episodic migraine and an acute
treatment for migraine attacks, AbbVie is pleased to present new
data across its migraine portfolio," said Michael Gold, M.D., therapeutic area head,
neuroscience development, AbbVie. "We continue to research
potential new indications that may help more people living with
this debilitating disease. Presenting robust data from our migraine
portfolio demonstrates our commitment to people living with
migraine and our goal of preserving personhood."
Researchers will present results from multiple migraine studies,
including a late-breaker poster presentation about the Phase 3
PROGRESS trial investigating the use of atogepant for preventive
treatment of chronic migraine. Data from this study will support a
supplemental New Drug Application (sNDA) with the U.S. Food and
Drug Administration for the expanded use of atogepant to include
the preventive treatment of chronic migraine, potentially building
on the current indication for the preventive treatment of episodic
migraine. This research will support regulatory submissions
globally as well.
Data also will be presented on ubrogepant (UBRELVY®)
for acute treatment of migraine and onabotulinumtoxinA
(BOTOX®) for the preventive treatment of chronic
migraine. In addition, results from the Combining UbRogepAnt and
Preventives for MiGrainE (COURAGE) study evaluating the real-world
effectiveness of ubrogepant for the acute treatment of migraine
when used in patients receiving onabotulinumtoxinA for the
preventive treatment of chronic migraine will be
presented.
AbbVie also will present interim U.S. results from the Chronic
Migraine Epidemiology and Outcomes International (CaMEO-I) study
focused on the use of preventive migraine treatment over the past
decade in comparison to the number of preventive-eligible people
with migraine who reported not currently using a preventive
medication. Further study results from CaMEO-I will be shared,
including U.S. interim results characterizing the pre- and
post-headache phases of migraine, neck pain in migraine, and
examining chronic migraine epidemiology and outcomes.
In addition, a retrospective claims database analysis will be
presented. This study evaluated the impact of step therapy
requirements on direct costs among people living with chronic
migraine within the Medicare fee-for-service population.
Key AbbVie abstracts and presentation details for the 2022 AHS
Annual Scientific Meeting are outlined below.
Abstract
Title
|
Presentation
Details
All Times
MDT
|
Atogepant
|
|
Post-hoc Analysis
Evaluating Safety of Atogepant in ADVANCE & Open-
Label Extension Participants with Cardiovascular Risk
Factors
|
Poster
(P-137)
Friday, June
10
1:30 – 2:30
PM
|
Safety and Tolerability
of Atogepant: A Post Hoc Analysis of Pooled Data
From Four Clinical Trials
|
Poster
(P-141)
Friday, June
10
1:30 – 2:30
PM
|
Decrease in Body Weight
With Once-Daily Atogepant for the Preventive
Treatment of Migraine: A Post Hoc Analysis
|
Oral
Presentation
Saturday, June
11
7:30 am – 9:30
am
|
Effect of High Fat Meal
on the Pharmacokinetics of an Immediate Release
Atogepant Tablet
|
Poster
(P-118)
Saturday, June
11
1:00 – 2:15
PM
|
Effects of CYP3A4
inhibition/induction, and OATP inhibition on the
pharmacokinetics of atogepant in healthy adults: Two phase 1,
open-label,
fixed-sequence, single-center, crossover trials
|
Poster
(P-120)
Saturday, June
11
1:00 – 2:15
PM
|
Monthly Migraine Days,
Acute Medication Use Days, and Migraine-Specific
Quality of Life in Responders to Atogepant: A Post Hoc
Analysis
|
Poster
(P-182)
Saturday, June
11
1:00 – 2:15
PM
|
Evaluation of the
Pharmacokinetic Interaction and Safety of Coadministered
Atogepant and Topiramate
|
Poster
(P-172)
Saturday, June
11
1:00 – 2:15
PM
|
Sustained Response to
Atogepant in Individuals with Episodic Migraine:
Post Hoc Analyses of 12- and 52-Week Phase 3 Trials
|
Poster
Saturday, June
11
1:00 – 2:15
PM
|
Subsequent Response to
Atogepant in Individuals with Episodic Migraine
after an Initial Inadequate Response: Post Hoc Analysis of a
12-week Phase
3 Trial
|
Poster
(P-200)
Saturday, June
11
1:00 – 2:15
PM
|
Atogepant for the
Preventive Treatment of Chronic Migraine: Results From
the PROGRESS Phase 3 Trial
|
Poster
(LB-P-04)
Saturday, June
11
1:00 – 2:15
PM
|
Ubrogepant
|
|
Real-World
Effectiveness of Ubrogepant Among Participants with Prior
Treatment Failure: Subgroup Analysis from the UNIVERSE
Study
|
Poster
(P-139)
Friday, June
10
1:30 – 2:30
PM
|
Within-Person
Consistency of Acute Treatment Success With Ubrogepant:
Results From a Long-term Safety Study
|
Poster
(P-208)
Saturday, June
11
1:00 – 2:15
PM
|
Participant-Reported
Normal Function and Satisfaction are Maintained with
Long-Term Intermittent Use of Ubrogepant
|
Poster
(P-134)
Saturday, June
11
1:00 – 2:15
PM
|
Real-World
Effectiveness of Ubrogepant for the Acute Treatment of Migraine
in Combination with OnabotulinumtoxinA Preventive: Results from
the
COURAGE Study
|
Poster
(P-190)
Saturday, June
11
1:00 – 2:15
PM
|
Treatment Satisfaction
and Optimization with Real-World Use of Ubrogepant
for the Acute Treatment of Migraine in Combination with
OnabotulinumtoxinA Preventive: Results from the COURAGE
Study
|
Poster
(P-147)
Saturday, June
11
1:00 – 2:15
PM
|
Within-Person Analysis
of Ubrogepant Treatment of Mild Versus Moderate-
Severe Headache Pain during a Phase 3 Long-Term Safety Extension
Trial
|
Poster
(P-148)
Saturday, June
11
1:00 – 2:15
PM
|
OnabotulinumtoxinA
|
|
Real-World Persistence
Rates for OnabotulinumtoxinA versus CGRP mAbs
Among Patients With Chronic Migraine: An Analysis of Electronic
Health
Record Data
|
Poster
(P-93)
Friday, June
10
1:30 – 2:30
PM
|
Real-World Persistence
and Costs Among Patients with Chronic Migraine
Treated With OnabotulinumtoxinA or CGRP mAbs: A Retrospective
Claims
Analysis Study
|
Poster
(P-92)
Saturday, June
11
1:00 – 2:15
PM
|
Evaluation of PREEMPT
fixed-dose, fixed-site and follow the pain treatment
paradigms in the PREDICT Study
|
Poster
(P-171)
Friday, June
10
1:30 – 2:30
PM
|
Impact of Step Therapy
for Chronic Migraine on Pharmacy Costs and
Healthcare Resource Utilization
|
Poster
(P-79)
Friday, June
10
1:30 – 2:30
PM
|
Migraine
disease
|
|
Impact of Monthly
Headache Days on Migraine-Related Quality of Life:
Results From the CaMEO Study
|
Poster
(P-21)
Friday, June
10
1:30 – 2:30
PM
|
The Association Between
Preventive Treatment Failure and Quality of Life
and Functioning Among Individuals with Low- and Moderate- to
High-
Frequency Episodic Migraine
|
Poster
(P-98)
Saturday, June
11
1:00 – 2:15
PM
|
Characterizing
Preventive Treatment Gaps in Migraine: Interim Results From
the CaMEO-International Study United States Sample
|
Oral
Presentation
Saturday, June
11
7:30 am – 9:30
am
|
Healthcare Resource
Utilization and Costs in Low- and Moderate- to High-
Frequency Episodic Migraine: Association with Preventive Treatment
Failure
|
Poster
(P-76)
Saturday, June
11
1:00 – 2:15
PM
|
Characterizing the Pre-
and Post-Headache Phases of Migraine: Interim
Results From the CaMEO-International Study (US Sample)
|
Poster
(P-11)
Friday, June
10
1:30 – 2:30
PM
|
Characterizing
Pre-Headache (Prodrome) Features of Migraine Attacks:
Results From the CaMEO Study
|
Poster
(P-10)
Friday, June
10
1:30 – 2:30
PM
|
Relative Frequency,
Healthcare Resource Utilization, and Costs of
Diagnosed Drug-Induced Headache and Potential Acute Medication
Overuse in Patients with Migraine
|
Poster
(P-96)
Saturday, June
11
1:00 – 2:15
PM
|
Chronic Migraine
Epidemiology and Outcomes – International (CaMEO-I)
Study: Methods and Interim US Findings for Gender and Changes
in
Diagnosis Rates Over Nearly a Decade
|
Poster
(P-43)
Friday, June
10
1:30 – 2:30
PM
|
Characterizing Neck
Pain in Migraine: Interim Results From the CaMEO-I
Study United States Sample
|
Poster
(P-42)
Saturday, June
11
1:00 – 2:15
PM
|
The 2022 AHS Annual Scientific Session agenda can be found
here.
About QULIPTA™ (atogepant)
QULIPTA™, which was approved by the U.S. Food and Drug
Administration (FDA) in September
2021, is available in the United
States as the first and only oral calcitonin gene-related
peptide (CGRP) receptor antagonist (gepant) specifically developed
for the preventive treatment of episodic migraine. CGRP and its
receptors are expressed in regions of the nervous system associated
with migraine pathophysiology, and studies have shown that CGRP
levels are elevated during migraine attacks. QULIPTA blocks CGRP
through a once-daily dose and is available in three strengths – 10
mg, 30 mg and 60 mg.
QULIPTA™ USE AND U.S. IMPORTANT SAFETY INFORMATION
QULIPTA is a prescription medicine used for the preventive
treatment of episodic migraine in adults.
Before taking QULIPTA, tell your healthcare provider about
all your medical conditions, including if you:
- Have kidney problems or are on dialysis
- Have liver problems
- Are pregnant or plan to become pregnant. It is not known if
QULIPTA will harm your unborn baby
- Are breastfeeding or plan to breastfeed. It is not known if
QULIPTA passes into your breast milk. Talk to your healthcare
provider about the best way to feed your baby while taking
QULIPTA
Tell your healthcare provider about all the medicines you
take, including prescription and over-the-counter medicines,
vitamins, and herbal supplements. QULIPTA may affect the way other
medicines work, and other medicines may affect how QULIPTA works.
Your healthcare provider may need to change the dose of QULIPTA
when taken with certain other medicines.
The most common side effects of QULIPTA are nausea,
constipation, and fatigue. These are not all the possible side
effects of QULIPTA.
Please see full Prescribing Information.
Globally, prescribing information varies; refer to the
individual country product label for complete information.
You are encouraged to report negative side effects of
prescription drugs to the FDA.
Visit www.fda.gov/medwatch or
call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie
may be able to help.
Visit AbbVie.com/myAbbVieAssist to learn
more.
About UBRELVY® (ubrogepant)
UBRELVY® is an orally administered
calcitonin gene-related peptide (CGRP) receptor antagonist (gepant)
for the acute treatment of migraine with or without aura in adults
that is an option for a wide range of patients who experience
migraine attacks. UBRELVY® is the first pill of its kind
to directly block CGRP, a protein released during a migraine
attack, from binding to its receptors.
UBRELVY® USE AND U.S. IMPORTANT SAFETY
INFORMATION
UBRELVY® is a prescription medicine
used for the acute treatment of migraine attacks with or without
aura in adults. UBRELVY® is not used to prevent migraine
headaches.
Who should not take UBRELVY®
(ubrogepant)?
Do not take UBRELVY® if you are
taking medicines known as strong CYP3A4 inhibitors, such as
ketoconazole, clarithromycin, or itraconazole.
What should I tell my healthcare provider before taking
UBRELVY®?
Tell your healthcare provider about all
your medical conditions, including if you:
- Have liver problems
- Have kidney problems
- Are pregnant or plan to become pregnant
- Are breastfeeding or plan to breastfeed
Tell your healthcare provider about all the medicines you
take, including prescription and over-the-counter
medicines, vitamins, and herbal supplements. Your healthcare
provider can tell you if it is safe to take UBRELVY®
with other medicines.
What are the most common side effects of
UBRELVY®?
The most common side effects are nausea (4%) and sleepiness
(3%). These are not all of the possible side effects of
UBRELVY®.
Please see full Prescribing Information.
Globally, prescribing information varies; refer to the
individual country product label for complete information.
You are encouraged to report negative side effects of
prescription drugs to the FDA.
Visit www.fda.gov/medwatch or
call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie
may be able to help.
Visit AbbVie.com/myAbbVieAssist to learn
more.
About BOTOX® (onabotulinumtoxinA)
BOTOX® was first approved by the FDA in 1989 for two
rare eye muscle disorders – blepharospasm and strabismus in adults.
Today, BOTOX® is FDA-approved for 12 therapeutic
indications, including chronic migraine, overactive bladder,
leakage of urine (incontinence) due to overactive bladder caused by
a neurologic condition in adults and in pediatric patients five
years of age and older, cervical dystonia, adult and pediatric
spasticity, and severe underarm sweating (axillary
hyperhidrosis).
BOTOX® (onabotulinumtoxinA) U.S.
Important Information
Indications
BOTOX® is a prescription medicine that is injected into
muscles and used:
- To treat overactive bladder symptoms such as a strong need to
urinate with leaking or wetting accidents (urge urinary
incontinence), a strong need to urinate right away (urgency), and
urinating often (frequency) in adults 18 years and older when
another type of medicine (anticholinergic) does not work well
enough or cannot be taken
- To treat leakage of urine (incontinence) in adults 18 years and
older with overactive bladder caused by a neurologic disease who
still have leakage or cannot tolerate the side effects after trying
an anticholinergic medication
- To treat overactive bladder due to a neurologic disease in
children 5 years of age and older when another type of medicine
(anticholinergic) does not work well enough or cannot be taken
- To prevent headaches in adults with chronic migraine who have
15 or more days each month with headache lasting 4 or more hours
each day in people 18 years or older
- To treat increased muscle stiffness in people 2 years of age
and older with spasticity
- To treat the abnormal head position and neck pain that happens
with cervical dystonia (CD) in people 16 years and older
- To treat certain types of eye muscle problems (strabismus) or
abnormal spasm of the eyelids (blepharospasm) in people 12 years of
age and older
BOTOX® is also injected into the skin to treat the
symptoms of severe underarm sweating (severe primary axillary
hyperhidrosis) when medicines used on the skin (topical) do not
work well enough in people 18 years and older.
It is not known whether BOTOX® is safe and effective
to prevent headaches in patients with migraine who have 14 or fewer
headache days each month (episodic migraine).
BOTOX® has not been shown to help people perform
task-specific functions with their upper limbs or increase movement
in joints that are permanently fixed in position by stiff
muscles.
It is not known whether BOTOX® is safe and effective
for severe sweating anywhere other than your armpits.
U.S. IMPORTANT SAFETY INFORMATION
BOTOX® may cause serious side effects
that can be life threatening. Get medical help right away if you
have any of these problems any time (hours to weeks) after
injection of BOTOX®:
- Problems swallowing, speaking, or breathing, due to
weakening of associated muscles, can be severe and result in loss
of life. You are at the highest risk if these problems are
pre-existing before injection. Swallowing problems may last for
several months
- Spread of toxin effects. The effect of botulinum toxin
may affect areas away from the injection site and cause serious
symptoms including: loss of strength and all-over muscle weakness,
double vision, blurred vision and drooping eyelids, hoarseness or
change or loss of voice, trouble saying words clearly, loss of
bladder control, trouble breathing, and trouble swallowing
There has not been a confirmed serious case of spread of toxin
effect away from the injection site when BOTOX® has been
used at the recommended dose to treat chronic migraine, severe
underarm sweating, blepharospasm, or strabismus.
BOTOX® may cause loss of strength or general muscle
weakness, vision problems, or dizziness within hours to weeks of
taking BOTOX®. If this happens, do not drive a car,
operate machinery, or do other dangerous activities.
Do not receive BOTOX® if you: are
allergic to any of the ingredients in BOTOX® (see
Medication Guide for ingredients); had an allergic reaction to
any other botulinum toxin product such as Myobloc®
(rimabotulinumtoxinB), Dysport® (abobotulinumtoxinA), or
Xeomin® (incobotulinumtoxinA); have a skin infection at
the planned injection site.
Do not receive BOTOX® for the
treatment of urinary incontinence if you: have a urinary tract
infection (UTI) or cannot empty your bladder on your own and are
not routinely catheterizing. Due to the risk of urinary retention
(not being able to empty the bladder), only patients who are
willing and able to initiate catheterization post treatment, if
required, should be considered for treatment.
Patients treated for overactive bladder:
In clinical trials, 36 of the 552 patients had to
self-catheterize for urinary retention following treatment with
BOTOX® compared to 2 of the 542 treated with
placebo. The median duration of post-injection catheterization for
these patients treated with BOTOX® 100 Units (n = 36)
was 63 days (minimum 1 day to maximum 214 days) as compared to a
median duration of 11 days (minimum 3 days to maximum 18 days) for
patients receiving placebo (n = 2). Patients with diabetes mellitus
treated with BOTOX® were more likely to develop urinary
retention than nondiabetics.
Adult Patients treated for overactive bladder due to
neurologic disease:
In clinical trials, 30.6% of patients (33/108) who were not
using clean intermittent catheterization (CIC) prior to injection,
required catheterization for urinary retention following treatment
with BOTOX® 200 Units as compared to 6.7% of
patients (7/104) treated with placebo. The median duration of
post-injection catheterization for these patients treated with
BOTOX® 200 Units (n = 33) was 289 days (minimum 1 day to
maximum 530 days) as compared to a median duration of 358 days
(minimum 2 days to maximum 379 days) for patients receiving placebo
(n = 7). Among patients not using CIC at baseline, those with MS
were more likely to require CIC post injection than those with
SCI.
The dose of BOTOX® is not the same as,
or comparable to, another botulinum toxin product.
Serious and/or immediate allergic reactions have been
reported, including itching, rash, red itchy welts, wheezing,
asthma symptoms, dizziness, or feeling faint. Get medical help
right away if you experience symptoms; further injection of
BOTOX® should be discontinued.
Tell your doctor about all your muscle or nerve
conditions, such as ALS or Lou
Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased
risk of serious side effects, including difficulty swallowing and
difficulty breathing from typical doses of BOTOX®.
Tell your doctor if you have any breathing-related
problems. Your doctor may monitor you for breathing problems
during treatment with BOTOX® for spasticity or for
detrusor overactivity associated with a neurologic condition. The
risk of developing lung disease in patients with reduced lung
function is increased in patients receiving BOTOX®.
Cornea problems have been reported. Cornea (surface of
the eye) problems have been reported in some people receiving
BOTOX® for their blepharospasm, especially in people
with certain nerve disorders. BOTOX® may cause the
eyelids to blink less, which could lead to the surface of the eye
being exposed to air more than is usual. Tell your doctor if you
experience any problems with your eyes while receiving
BOTOX®. Your doctor may treat your eyes with drops,
ointments, contact lenses, or with an eye patch.
Bleeding behind the eye has been reported. Bleeding
behind the eyeball has been reported in some people receiving
BOTOX® for their strabismus. Tell your doctor if you
notice any new visual problems while receiving
BOTOX®.
Bronchitis and upper respiratory tract infections (common
colds) have been reported. Bronchitis was reported more
frequently in adults receiving BOTOX® for upper limb
spasticity. Upper respiratory infections were also reported more
frequently in adults with prior breathing-related problems with
spasticity. In pediatric patients treated with BOTOX®
for upper limb spasticity, upper respiratory tract infections were
reported more frequently. In pediatric patients treated with
BOTOX® for lower limb spasticity, upper respiratory
tract infections were not reported more frequently than
placebo.
Autonomic dysreflexia in patients treated for overactive
bladder due to neurologic disease. Autonomic dysreflexia
associated with intradetrusor injections of BOTOX® could
occur in patients treated for detrusor overactivity associated with
a neurologic condition and may require prompt medical therapy. In
clinical trials, the incidence of autonomic dysreflexia was greater
in adult patients treated with BOTOX® 200 Units compared
with placebo (1.5% versus 0.4%, respectively).
Tell your doctor about all your medical conditions, including
if you: have or have had bleeding problems; have plans to have
surgery; had surgery on your face; weakness of forehead muscles;
trouble raising your eyebrows; drooping eyelids; any other abnormal
facial change; have symptoms of a urinary tract infection (UTI) and
are being treated for urinary incontinence (symptoms of a urinary
tract infection may include pain or burning with urination,
frequent urination, or fever); have problems emptying your bladder
on your own and are being treated for urinary incontinence; are
pregnant or plan to become pregnant (it is not known if
BOTOX® can harm your unborn baby); are breastfeeding or
plan to (it is not known if BOTOX® passes into breast
milk).
Tell your doctor about all the medicines you take,
including prescription and over-the-counter medicines, vitamins,
and herbal supplements. Using BOTOX® with certain other
medicines may cause serious side effects. Do not start any new
medicines until you have told your doctor that you have received
BOTOX® in the past.
Tell your doctor if you received any other botulinum toxin
product in the last 4 months; have received injections of botulinum
toxin such as Myobloc®,
Dysport®, or Xeomin® in the
past (tell your doctor exactly which product you received); have
recently received an antibiotic by injection; take muscle
relaxants; take an allergy or cold medicine; take a sleep medicine;
take aspirin-like products or blood thinners.
Other side effects of
BOTOX® include: dry mouth, discomfort or
pain at the injection site, tiredness, headache, neck pain, eye
problems: double vision, blurred vision, decreased eyesight,
drooping eyelids, swelling of your eyelids, dry eyes; drooping
eyebrows; and upper respiratory tract infection. In adults being
treated for urinary incontinence, other side effects include
urinary tract infection and painful urination. In children being
treated for urinary incontinence, other side effects include
urinary tract infection and bacteria in the urine. If you have
difficulty fully emptying your bladder on your own after receiving
BOTOX®, you may need to use disposable self-catheters to
empty your bladder up to a few times each day until your bladder is
able to start emptying again.
For more information refer to the Medication Guide or talk
with your doctor.
Please see BOTOX® full Product
Information, including Boxed Warning and Medication
Guide.
Globally, prescribing information varies; refer to
the individual country product label for complete information.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit
www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie
may be able to help.
Visit AbbVie.com/myAbbVieAssist to learn
more.
About AbbVie in Migraine
At AbbVie, we are committed to empowering people living with
migraine disease. We advance science that enables health care
providers to care for people impacted across the spectrum of
migraine. Through education and partnerships with the migraine
community, we strive to help those with migraine navigate barriers
to care, access effective treatments and reduce the impact of
migraine on their lives.
About AbbVie in Neuroscience
At AbbVie, our commitment to preserve the personhood of those
living with neurological and psychiatric disorders is unwavering.
Every challenge in this uncharted territory makes us more
determined and drives us harder to discover and deliver solutions
for patients, care partners and clinicians. AbbVie's Neuroscience
portfolio consists of approved therapies in neurological and
psychiatric disorders including bipolar I disorder, cervical
dystonia, major depressive disorder, migraine, Parkinson's disease,
post-stroke spasticity, schizophrenia, and others along with a
robust pipeline.
We have a strong investment in neuroscience research, with our
Foundational Neuroscience Center in Cambridge, Massachusetts, and our Neuroscience
Discovery site in Ludwigshafen, Germany, where our research and resilience in
these challenging therapeutic areas is yielding a deeper
understanding of the pathophysiology of neurological and
psychiatric disorders and identifying targets for potential
disease-modifying therapeutics aimed at making a difference in
people's lives.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
that solve serious health issues today and address the medical
challenges of tomorrow. We strive to have a remarkable impact on
people's lives across several key therapeutic areas: immunology,
oncology, neuroscience, eye care, virology, women's health and
gastroenterology, in addition to products and services across our
Allergan Aesthetics portfolio. For more information about AbbVie,
please visit us at www.abbvie.com. Follow @abbvie on Twitter,
Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statements
Some statements in this news release are, or may be
considered, forward-looking statements for purposes of the Private
Securities Litigation Reform Act of 1995. The words "believe,"
"expect," "anticipate," "project" and similar expressions, among
others, generally identify forward-looking statements. AbbVie
cautions that these forward-looking statements are subject to risks
and uncertainties that may cause actual results to differ
materially from those indicated in the forward-looking statements.
Such risks and uncertainties include, but are not limited to,
failure to realize the expected benefits from AbbVie's acquisition
of Allergan plc ("Allergan"), failure to promptly and effectively
integrate Allergan's businesses, competition from other products,
challenges to intellectual property, difficulties inherent in the
research and development process, adverse litigation or government
action, changes to laws and regulations applicable to our industry
and the impact of public health outbreaks, epidemics or pandemics,
such as COVID-19. Additional information about the economic,
competitive, governmental, technological and other factors that may
affect AbbVie's operations is set forth in Item 1A, "Risk Factors,"
of AbbVie's 2021 Annual Report on Form 10-K, which has been filed
with the Securities and Exchange Commission, as updated by its
subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no
obligation to release publicly any revisions to forward-looking
statements as a result of subsequent events or developments, except
as required by law.
View original
content:https://www.prnewswire.com/news-releases/abbvie-to-present-extensive-data-from-its-migraine-portfolio-at-the-2022-american-headache-society-ahs-annual-scientific-meeting-301562618.html
SOURCE AbbVie